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Older age consistently relates to a lesser ability to fully recover from a traumatic brain
injury (TBI); however, there is limited data to explicate the nature of age-related risks. This
study was undertaken to determine the relationship of age on gene-activity following a
TBI, and how this biomarker relates to changes in neuroimaging findings. A young group
(between the ages of 19 and 35 years), and an old group (between the ages of 60 and
89 years) were compared on global gene-activity within 48 h following a TBI, and then
at follow-up within 1-week. At each time-point, gene expression profiles, and imaging
findings from both magnetic resonance imaging (MRI) and computed tomography were
obtained and compared. The young group was found to have greater gene expression of
inflammatory regulatory genes at 48 h and 1-week in genes such as basic leucine zipper
transcription factor 2 (BACH2), leucine-rich repeat neuronal 3 (LRRN3), and lymphoid
enhancer-binding factor 1 (LEF1) compared to the old group. In the old group, there
was increased activity in genes within S100 family, including calcium binding protein
P (S100P) and S100 calcium binding protein A8 (S100A8), which previous studies
have linked to poor recovery from TBI. The old group also had reduced activity of the
noggin (NOG) gene, which is a member of the transforming growth factor-β superfamily
and is linked to neurorecovery and neuroregeneration compared to the young group.
We link these gene expression findings that were validated to neuroimaging, reporting
that in the old group with a MRI finding of TBI-related damage, there was a lesser
likelihood to then have a negative MRI finding at follow-up compared to the young
group. Together, these data indicate that age impacts gene activity following a TBI,
and suggest that this differential activity related to immune regulation and neurorecovery
contributes to a lesser likelihood of neuronal recovery in older patients as indicated
through neuroimaging.
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INTRODUCTION
Traumatic brain injuries (TBIs) occur in about 5% of individuals
over 60 years of age, and place them at a far greater risk for
morbidity and mortality following TBI compared to younger
cohorts (Ghorbani et al., 2014). In both the general population,
and in older individuals, most TBIs are mild in severity and
result in short-lasting symptoms (Centers for Disease Control
and Prevention [CDC], National Center for Injury Prevention
and Control, 2003, 2014); however, approximately 10% of mild
TBI subjects do not fully recover (Carroll et al., 2004; Kashluba
et al., 2008). Part of the heterogeneity in recovery from TBI is
related to age, with older subjects being consistently at higher
risk for poor or partial recovery (McIntyre et al., 2013; Sherer
et al., 2015). Hukkelhoven et al. (2003) reported that the odds for
a poor outcome following TBI increases by 40–50% per every 10
years of age, with those patients who are 60 years or older being at
four times greater risk to not fully recover compared to a 30-year-
old TBI patient. The age-related risk observed by Hukkelhoven
et al. (2003) relates to insufficient recovery processes, as opposed
to injury severity or type of injury. This illustrates that age-
related factors contribute to poor recovery, and that a better
understanding of the mechanisms of age-related compromise
may inform the development of therapeutic interventions to
mitigate age-related risk. In further support of this link, adults
above 60 years of age with similar severity and type of injury more
often require neurosurgical intervention following a moderate or
severe TBI (Tierney et al., 2015). Following a mild TBI, being
over 60 is the only independent predictor of insufficient recovery
(Tierney et al., 2015). It is therefore important to develop a greater
understanding of the pathophysiological processes following TBI
which will ultimately improve diagnostics and interventions to
reduce this age-related risk for older patients who sustained a TBI
(Mellergard et al., 2012).
The higher morbidity and mortality rates in older TBI patients
strongly suggest that age impacts neurological recovery following
a TBI (Adekoya et al., 2002). TBIs place the brain at risk for
accelerated aging, with the brains of TBI subjects appearing
5 years older than controls (Cole et al., 2015). Further, older
patients who sustain a TBI are approximately 40% more likely to
develop neurodegenerative disorders such as Parkinson’s disease
(Gardner et al., 2015) and dementia (Gardner et al., 2014), a
risk that is not observed in younger subjects. Together these
studies illustrate that the consequences of TBI differ between the
old and the young, suggesting the presence of distinct biological
mechanisms underlying age-related differences in the response to
TBI, that currently are poorly understood.
Aging affects a plethora of pathways important in the response
to brain injury. Studies show that older patients with a TBI have
greater alterations in blood–brain barrier (BBB) permeability,
which may contribute to tissue damage after TBI (Farrall and
Wardlaw, 2009) or stroke (Zeevi et al., 2010). Neuroinflammatory
processes also differ between the young and old (Ritzel et al.,
2015), with preclinical models consistently linking poor recovery
to advanced age, a relationship mediated in part through greater
neuroinflammation (Kumar et al., 2013; Webster et al., 2015;
Gupta and Prasad, 2016). Furthermore, systemic immune system
activity, drug metabolism and neuroendocrine processes are
attenuated by the aging process (Gruver et al., 2007; Cekic and
Stein, 2010) and likely contribute to insufficient recovery from
brain injury in older individuals. Therefore we postulate that
these age-related differences can be determined by comparing
young and old patients who sustain a TBI through global gene-
expression differences. We expect this line of research to provide
a better understanding of the age-related molecular mechanisms
that contribute to poor recovery in older TBI patients, and
to ultimately lead to the identification or development of
targeted therapeutic interventions to mitigate age-related TBI
impairments.
Gene expression profiles provide an opportunity to under-
stand how complex biological systems relate to TBI (Michael
et al., 2005; Staffa et al., 2012; Heinzelmann et al., 2014). Both
preclinical and clinical studies have reported significant changes
in gene expression following a TBI (Lu et al., 2004), however,
a clear biomarker of this injury has yet to be determined (Barr
et al., 2011). A plausible reason for this is that whereas preclinical
studies are able to examine neuronal gene-activity changes
clinical studies are restricted to the used of primarily peripheral
blood. An example of this is a recent study in a rat model of
TBI which showed that brain tissue-related changes in gene-
activity were related to cell death and survival gene pathways
(White et al., 2016), as well as inflammation gene-pathways (Sabir
et al., 2015). Within preclinical studies, there are both studies
using in vitro and in vivo induced TBI models, with a very
interesting study that compared both models using a genome-
wide approach to have differential gene expression related to
genes that direct the function of amyloid precursor protein to the
recycling pathway by direct binding and away from amyloid beta
producing enzymes, in both TBI models (Lamprecht et al., 2016).
Preclinical studies also highlight the ability of these models to use
of peripheral gene expression in the pathophysiological processes
following TBI (Hernandez-Ontiveros et al., 2013; Woodcock
and Morganti-Kossmann, 2013). Therefore, these preclinical
models provide invaluable insights into TBI-related gene-activity
changes that cannot be determined in clinical studies.
In clinical studies, the examination of peripheral gene
expression is supported by research demonstrating that central
nervous system microglia communicate with peripheral immune
cells, and that this interaction results in alterations in peripheral
immune cell gene expression that can be detected in venous
blood following TBIs (Raghavendra Rao et al., 2003; Woodcock
and Morganti-Kossmann, 2013). Moreover, peripheral immune
cells have access to, and are actively recruited to the meninges
and parenchyma to participate in the protection and repair of
neuronal and supporting cells and functional recovery (Schwartz
et al., 2013). Evidence from our group (Heinzelmann et al., 2014)
suggests that there are clinically relevant differences in gene
expression in peripheral immune cells in TBI patients compared
to controls. Other clinical studies also report down regulation of
olfactory receptor genes in the peripheral blood following a TBI,
which was linked to abnormal tau phosphorylation (Zhao et al.,
2013); however, this study only examined gene expression at one
time-point. Therefore, previous studies suggest that peripheral
blood gene expression changes relate to TBIs. In the only known
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study to examine the impact of age in relation to TBI recovery and
role of genetic predisposition, polymorphisms in brain-derived
neurotrophic factor interacted with age following severe TBI
and related to mortality risk (Failla et al., 2015); however, gene-
function was not determined. These studies did not explicate
the association between gene expression and tissue recovery
evidenced in imaging scans, and even fewer studies compare
processes in young and old patients, thereby limiting our ability
to develop improved diagnostics, therapeutic screenings, and
interventions for older patients with TBI (Mellergard et al., 2012).
In the present study, we describe the impact of age on recovery
and biomarkers related to this by gene expression changes
following TBI. We examined gene expression from peripheral
blood during the acute period (within 48 h) and at follow-up
(1-week), and examined age by comparing two groups, a young
group (19–35 years old) and an old group (60–89 years old). We
also compared the presence or absence of TBI-related magnetic
resonance imaging (MRI) findings over time in both age groups.
Possible links between gene expression and imaging findings may
provide insights into which genes may serve as therapeutic target
to promote recovery in older TBI patients.
MATERIALS AND METHODS
Subjects
The Center for Neuroscience and Regenerative Medicine
Traumatic Head Injury Neuroimaging Classification protocol
(NCT01132937) enrolled subjects who had sustained a head
injury within 48 h prior to presentation at either MedStar
Washington Hospital Center (WHC), Washington, DC, USA
or Johns Hopkins Suburban Hospital (SH), Bethesda, MD,
USA. The protocol was approved by the National Institutes
of Health Intramural Institutional Review Board, and all
research was conducted in accordance with the committee’s
recommendations. Prior to study procedures, written informed
consent was obtained from all subjects. In order to test the
difference by age, only two groups were compared; the young
(19–35 years old, n = 33) and the old groups (60–89 years old,
n = 33), while the intermediate age group (36–59 years old)
was not analyzed further in this study to avoid the potential
confounder of fluctuating levels of sex steroid hormones during
the perimenopausal stage.
Imaging
A conventional non-contrast computed tomography (CT) scan
was obtained for clinical purposes. Following consent, a research
MRI was obtained. MRI was conducted at two time points;
within 48 h and 1-week post-injury. A standardized MRI
protocol of approximately 25 min in duration was used
which included: diffusion-weighted imaging (DWI), two T2∗-
weighted sequences, pre- and post-contrast fluid-attenuated
inversion recovery, 3D high resolution T1, and dynamic
susceptibility contrast perfusion-weighted imaging. Depending
on local site policy, subjects were administered one dose
of a gadolinium based contrast agent, either 0.1 mmol/kg
gadopentetate dimeglumine (Bayer HealthCare, Leverkusen,
Germany) or gadobenate dimeglumine (Bracco Diagnostics,
Monroe Township, NJ, USA). A power injector at 5 ml/s through
a 22-18 gauge needle administered contrast to the antecubital
vein. Images were obtained from 1.5 T (GE Medical Systems,
Milwaukee, WI, USA) at SH and a 3 T (Philips, Cleveland, OH,
USA) at WHC.
Clinical Symptoms
Injury severity at initial presentation was assessed using the
Glasgow Coma Scale (GCS; Teasdale and Jennett, 1974). The GCS
is scored between 3 (worst) and 15 (no impairment), based on a
patient’s eye response, verbal response, and motor response. The
representative score is the total GCS score (Teasdale and Jennett,
1974). The severity of each symptom on the Neurobehavioral
Symptom Inventory (NSI) was also measured using a 5-item scale
[0 (none) to 4 (very severe)] that asks subjects to indicate the
extent to which each symptom has disturbed them (Vanderploeg
et al., 2015). These scores were obtained twice, at baseline within
48 h of injury and 1-week post-injury. The total score is the
sum of cluster scores (vestibular, somatic sensory, cognitive, and
affective). Total scores can range from 0 to 88, with 88 being the
most severe (Vanderploeg et al., 2015).
Microarray
Peripheral blood samples were collected in PAXgene blood RNA
tubes at 48 h and 1-week post-injury. PAXgene tubes were
incubated at room temperature for 2 h, at −20◦C overnight, and
then at −80◦C until further processing. Total RNA was isolated
using the PAXgene blood RNA kit (PreAnalytiX, QIAGEN,
Venlo, Limburg, Netherlands) according to the manufacturer’s
protocol. Using the GeneChip 3′ IVT Plus Expression kit
(Affymetrix, Santa Clara, CA, USA), each RNA sample (100 ng)
was reverse transcribed, converted to biotinylated cRNA, and
hybridized to Affymetrix Human Genome U133 Plus 2.0
microarrays (Affymetrix, Santa Clara, CA, USA).
Quantitative Real-Time PCR
Quantitative real-time PCR was performed with five genes
selected from significantly upregulated genes in the young
group at 48 h post-injury. Three genes, leucine-rich repeat
neuronal 3 (LRRN3), POU2AF1, and noggin (NOG) were
among top 5 upregulated genes and BACH2, PITPNC1 were
randomly chosen. Two reference genes, TRAP1 and DECR1
were used to normalize data (Stamova et al., 2009). One
microgram of total RNA of each subject was reverse transcribed
using High-Capacity cDNA reverse transcription kits (Applied
Biosystems, Foster City, CA, USA). Quantitative real-time PCR
was performed with TaqMan R© probes in QuantStudioTM 6
Flex Real-Time PCR system (Applied Biosystems, Foster City,
CA, USA) with a total volume of 5 µl. PCR assay was
performed in triplicate under the following condition based
on the manufacture’s protocol; one cycle of 2 min at 50◦C;
10 min at 95◦C; and 40 cycles of 15 s at 95◦C, and 1 min at
60◦C. The instrumental software was used to get normalized
threshold cycle (1Ct) values, which were obtained from each
subject by subtracting Ct of reference genes from Ct of target
genes.
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Statistical Analysis
Microarray data were analyzed with Partek Genomics Suite
version 6.6 (Partek Inc., St. Louis, MO, USA). We used the
standard gene expression workflow in the Partek Genomics Suite.
Gene expression was normalized by using “Standardize” option,
which shifts genes to mean of 0 and scale to standard deviation
of 1. For differential expression, we used ANOVA. We considered
the age as the ANOVA factor and added contrast to get the fold
change and ratio between the phenotype and control. Multiple
testing correction was performed on the p-values to get the false
discovery rates (FDR). We chose the genes with fold change
greater than 1.5 and with the FDR smaller than 0.05. QIAGEN’s
Ingenuity Pathway Analysis (IPA, QIAGEN, Venlo, Limburg,
Netherlands) was used to determine which diseases and disorders
related to observed gene expression changes, as well as top-gene
networks implicated in these gene expression changes. Two-
tailed chi-square tests were used in demographic features such as
sex, race, ethnicity, frequency/duration of loss of consciousness
(LOC)/post-traumatic amnesia (PTA), and injury mechanism to
investigate the differences between age groups using SPSS version
22.0 (SPSS Inc., Chicago, IL, USA). The number of subject whose
GCS is less than 15 was compared between age groups with two-
tailed chi-square tests. Total NSI score from each two time points
was compared between age groups with Mann–Whitney test.
Differences were considered to be statistically significant when
p< 0.05.
RESULTS
A total of 66 subjects were included in this study, of which
48 subjects had follow-up data at 1-week post-TBI. The
demographic and clinical features of the total group (n = 66)
as well as the young (n = 33) and old groups (n = 33) are
described in Table 1. The majority of subjects were males (69.7%),
and Caucasians (89.4%) with more than half experiencing LOC
and PTA. There were no statistical differences in gender or
race between groups. However, the young group experienced
significantly more LOC (p = 0.006) and PTA (p = 0.012) than
the old group. The most common mechanism of TBI was direct
impact related to falls and motor vehicle accidents for both young
and old groups.
The median score of GCS was between 14 and 15 (mild TBI)
at each time point for both groups. Most of the subjects were
mild TBI (GCS 14–15), and their interquartile range were 15.
Therefore, we compared subjects whose GCS was less than 15
from each group, which was not significantly different between
groups. The distribution of those with 15 was not different
between these groups at any time-point. Self-reported symptoms
were obtained using the NSI at 48 h and 1-week post-TBI with
sub-cluster scores and the total score. At both time points, all
NSI scores were higher in the young group compared to the old
group.
CT scan results indicated that the young group has
significantly fewer TBI positive findings than the old group
(9.38 vs. 54.55%, respectively, p < 0.001) within 48 h post-TBI
(Table 2). In contrast, MRI showed that the majority of subjects
in both groups (about 75%) had evidence of a TBI within 48 h
of injury. At the 1-week follow-up, the number of subjects with a
positive MRI for TBI-related findings was significantly decreased
in the young group (from 72 to 32%; p = 0.002), but not in the
old group (75 to 76%).
To begin exploring underlying pathways, we undertook a
gene expression profiling analysis from peripheral whole blood
at both 48 h and 1-week post-TBI and compared the young and
old groups at both time-points. QC metrics of 66 subjects were
shown in Supplementary Figure S1. Based on ANOVA result,
the volcano plot displays significantly expressed genes against
fold-change and adjusted p-value at 48 h post-TBI (Figure 1).
At 48 h post-TBI, we found 56 transcripts annotated to 42
genes that were significantly upregulated in the young group,
which include: LRRN3, NOG, and tumor necrosis factor receptor
superfamily, member 17 (TNFRSF17; Table 3). Table 4 shows
classification of those genes based on their network functions.
Genes associated with neurological and inflammation diseases
were shown at Table 5. Five transcripts annotated to five genes
were significantly upregulated in the old group including at 48 h
TABLE 1 | Demographic and clinical characteristics of the young and the
old groups at 48 h and 1-week post-injury.
Variable Young group Old group p-value
No. 33 33
Male, n (%) 26 (78.8) 20 (60.6) 0.180
Age, median (IQR) 27.6 (23–32) 67.5 (64–80) <0.001
Race, n (%)
Caucasian 28 (84.8) 31 (93.9) 0.230
Latino/Hispanic 11 (33.33) 2 (6.06) 0.005
Post-traumatic amnesia, n (%) 25 (75.8) 15 (45.5) 0.012
Post-traumatic amnesia duration, n (%)
1 s to 10 min 10 (40.00) 4 (26.67) 0.247
10 min to 30 min 4 (16.00) 5 (33.33)
30 min to 1 h 5 (20.00) 0 (0.00)
1 h to 12 h 3 (12.00%) 2 (13.33)
12 h to 24 h 1 (4.00) 0 (0.00)
Unknown 1 (4.00) 3 (20.00)
Loss of consciousness, n (%) 27 (81.8) 14 (42.4) 0.006
Loss of consciousness duration, n (%)
<1 min 4 (14.81) 1 (5.26) 0.155
1 min to 29 min 16 (59.26) 8 (42.11)
30 min to 59 min 0 (0.00) 0 (0.00)
1 h to 24 h 1 (3.70) 0 (0.00)
Unknown 6 (22.22) 10 (52.63)
GCS 48 h while admitted <15, n (%) 7 (21.2) 10 (30.3) 0.677
NSI total 48 h, median (IQR) 15.0 (11–26) 10.0 (4–28) 0.004
NSI total 1 week, median (IQR) 9.0 (4–19) 8.0 (1–14) 0.136
Injury mechanism, n (%)
Acceleration/deceleration 5 (15.15) 1 (3.03) 0.551
Direct impact (blow to head) 7 (21.21) 9 (27.27)
Direct impact (head against object) 8 (24.24) 9 (27.27)
Fall (ground floor) 7 (21.21) 8 (24.24)
Fall (height > 1 m) 6 (21.21) 6 (18.18)
IQR, interquartile range.
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TABLE 2 | CT and MRI data at 48 h and 1-week post-injury for both groups.
48 h (n = 66) 1 week (n = 48)
Young group (n = 33) Old group (n = 33) p-value Young group (n = 25) Old group (n = 23) p-value
CT
TBI (+) 3/32 (9.38%) 18/33 (54.55%) <0.001
Intracerebral hemorrhage 1/32 (3.13%) 4/33 (12.12%) 0.174
MRI
TBI (+) 24/33 (72.72%)# 25/33 (75.76%) 0.778 8/25 (32.00%)# 16/21 (76.19%) 0.003
TBI (+) only at 48 h (=resolve) 13/24 (54.17%) 2/21 (9.52%) 0.002
TBI no change in 1-week 8/24 (33.33%) 15/21 (71.43%) 0.017
TBI (+) only at 1-week 3/24 (12.5%) 4/21 (19.05%) 0.545
This table describes initial findings at 48 h, and changes in the MRI scans at 1 week.
#p < 0.05 between the 48 h and 1-week in the same group.
FIGURE 1 | A volcano plot that shows differentially expressed genes
with statistical significance and fold change in the young and the old
group. Significant genes were selected by fold change (>1.5- or < −1.5-fold)
and adjusted p-value (<0.05). Each dot denotes a gene. It was colored by
adjusted p-value as shown in the legend. Fold change was evaluated as the
ratio of the old to the young.
post-TBI: S100 calcium binding protein P (S100P), and S100
calcium binding protein A8 (S100A8; Table 6). At 1-week post-
TBI, we found 48 transcripts annotated to 28 genes that were
significantly upregulated in the young group, including 19 genes
that were also upregulated at the 48 h time period (67.86%;
Table 3). In the old group, only one gene was significantly
upregulated at 1-week, which was BCAT1 (1.858 fold change).
In order to verify the microarray result, quantitative real-
time PCR was performed with five genes including LRRN3,
POU2AF1, NOG, BACH2, and PITPNC1, which are upregulated
in the young group at 48 h post-TBI and compared between
young and old groups. Among five genes, the expression
level of LRRN3, POU2AF1, and NOG was significantly higher
in the young group, which correlates with microarray data
(Supplementary Figure S2).
DISCUSSION
The higher morbidity and mortality rates consistently reported
in older TBI patients strongly suggest that age impacts the
neurological recovery response to TBI (Adekoya et al., 2002).
In this study, for the first time we report gene expression
differences in the young group (19–35 years old) and the
old group (60–89 years old), with the young group having
greater regulation of inflammatory activity, whereas the old
group had more activity in S100 genes, which have previously
been linked to TBIs. In addition to these gene expression
differences, we also report that the young group had relatively
improved neuronal recovery, as indicated by more subjects
having no MRI evidence of TBI at follow-up compared to older
subjects, despite similar MRI findings at 48 h following a TBI.
Further, we used an alternative method, quantitative real time
PCR to validate the gene expression differences determined
through microarrays. These imaging findings suggest differences
in neuronal recovery; however, the younger subjects endorsed
far more TBI-related symptoms at both time-points. To the
best of our knowledge, this is the first report to characterize
the influence of aging on gene expression activity and its
relationship to neuronal recovery by pairing biomarkers to
imaging findings. These results suggest that there is a biological
correlate for the long-established clinical observation of impaired
recovery from neurological injury from TBIs in older TBI
patients.
In this study, we report changes in several immune markers
that suggest a down-regulation of B cell activities in the old TBI
group. In our IPA, we identify 17 genes that are downregulated
and one gene upregulated in the old group that are associated
with the humoral immune response including immunoglobulin
heavy constant alpha 1 (IGHA1), immunoglobulin lambda
constant 1 (Mcg marker; IGLC1), and immunoglobulin J
polypeptide, linker protein for immunoglobulin alpha and mu
polypeptides (IGJ). The downregulation of these genes and
the upregulation of ITGB2 suggest that there may be an
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TABLE 3 | Upregulated genes in the young compared to the old group at 48 h post-injury and its change at 1-week post-injury.
Symbol Gene name False discovery rate
(q-value) at 48 h
Fold change
at 48 h
False discovery
rate (q-value) at
1-week
Fold change
at 1-week
LRRN3 Leucine-rich repeat neuronal 3 0.008 2.849∗ 0.005 3.692∗
IGHA1 Immunoglobulin heavy constant alpha 1 0.023 2.039∗ 0.123 2.600∗
IGJ Immunoglobulin J polypeptide, linker protein for immunoglobulin alpha
and mu polypeptides
0.030 1.941∗ 0.195 2.331∗
POU2AF1 POU class 2 associating factor 1 0.010 1.879∗ 0.027 1.965∗
NOG Noggin 0.010 1.852∗ 0.005 2.234∗
IGLC1 Immunoglobulin lambda constant 1 (Mcg marker) 0.027 1.784∗ 0.043 2.220∗
EBF1 Early B cell factor 1 0.015 1.767∗ 0.141 1.592∗
PAX5 Paired box 5 0.019 1.763∗ 0.098 1.770∗
NT5E 5′-nucleotidase, ecto (CD73) 0.012 1.736∗ 0.021 1.656∗
IGHG1 Immunoglobulin heavy constant gamma 1 (G1m marker) 0.032 1.731∗ 0.163 2.407∗
AFF3 AF4/FMR2 family, member 3 0.031 1.689∗ 0.192 1.630∗
SF1 Splicing factor 1 0.016 1.667∗ 0.363 1.532∗
TNFRSF17 Tumor necrosis factor (TNF) receptor superfamily, member 17 0.029 1.664∗ 0.448 1.465
HIP1 Huntingtin interacting protein 1 0.030 1.656∗ 0.552 1.378
ZBTB20 Zinc finger and BTB domain containing 20 0.008 1.619∗ 0.122 1.523∗
IGHD Immunoglobulin heavy constant delta 0.029 1.619∗ 0.379 1.408
BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 0.028 1.616∗ 0.019 1.849∗
BLNK B cell linker 0.029 1.615∗ 0.145 1.609∗
CAMK4 Calcium/calmodulin-dependent protein kinase IV 0.031 1.615∗ 0.179 1.696∗
STRBP Spermatid perinuclear RNA binding protein 0.010 1.598∗ 0.021 1.584∗
IGKC Immunoglobulin kappa constant 0.008 1.597∗ 0.161 1.325
FCRL5 Fc receptor-like 5 0.032 1.589∗ 0.514 1.333
SLC16A10 Solute carrier family 16 (aromatic amino acid transporter), member 10 0.012 1.581∗ 0.076 1.479
PITPNC1 Phosphatidylinositol transfer protein, cytoplasmic 1 0.006 1.575∗ 0.179 1.611∗
TSPAN13 Tetraspanin 13 0.027 1.575∗ 0.146 1.541∗
KLHL24 Kelch-like family member 24 0.021 1.569∗ 0.515 1.268
ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1 0.021 1.565∗ 0.296 1.359
AUTS2 Autism susceptibility candidate 2 0.010 1.564∗ 0.057 1.726∗
CDCA7L Cell division cycle associated 7-like 0.004 1.561∗ 0.005 1.505∗
OSBPL10 Oxysterol binding protein-like 10 0.025 1.557∗ 0.119 1.545∗
ABLIM1 Actin binding LIM protein 1 0.019 1.556∗ 0.024 1.725∗
IQGAP1 IQ motif containing GTPase activating protein 1 0.030 1.543∗ 0.697 1.281
P2RY10 Purinergic receptor P2Y, G-protein coupled, 10 0.032 1.541∗ 0.077 1.617∗
LEF1 Lymphoid enhancer-binding factor 1 0.037 1.539∗ 0.046 1.896∗
ERAP1 Endoplasmic reticulum aminopeptidase 1 0.017 1.531∗ 0.383 1.455
HSP90AB1 Heat shock protein 90 kDa alpha (cytosolic), class B member 1 0.025 1.525∗ 0.321 1.554∗
AGMAT Agmatineureohydrolase (agmatinase) 0.029 1.519∗ 0.018 1.724∗
MS4A1 Membrane-spanning 4-domains, subfamily A, member 1 0.037 1.517∗ 0.193 1.645∗
WLS wntless Wnt ligand secretion mediator 0.031 1.514∗ 0.590 1.373
TPD52 Tumor protein D52 0.032 1.510∗ 0.266 1.392
TCL1A T cell leukemia/lymphoma 1A 0.041 1.507∗ 0.411 1.476
IGHM Immunoglobulin heavy constant mu 0.019 1.503∗ 0.064 1.548∗
SGK223 Homolog of rat pragma of Rnd2 0.028 1.419 0.005 1.671∗
FAIM3 Fas apoptotic inhibitory molecule 3 0.040 1.363 0.021 1.665∗
AQP3 Aquaporin 3 (gill blood group) 0.045 1.470 0.034 1.658∗
TRAF5 TNF receptor-associated factor 5 0.049 1.416 0.043 1.642∗
PLXDC1 Plexin domain containing 1 0.029 1.327 0.001 1.595∗
MAN1C1 Mannosidase, alpha, class 1C, member 1 0.054 1.322 0.033 1.561∗
SCML1 Sex comb on midleg-like 1 (Drosophila) 0.019 1.460 0.020 1.527∗
ZNF827 Zinc finger protein 827 0.052 1.322 0.031 1.513∗
TCF4 Transcription factor 4 0.029 1.415 0.043 1.502∗
Significance level was set at 1.5-fold change.
∗ Identifies genes with a significant fold change.
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TABLE 4 | Functional classification of significantly upregulated genes in
young group at 48 h post-injury.
Functions Genes
Cell-to-cell signaling and interaction,
cellular development, cellular growth
and proliferation (score = 27)
BACH2, CAMK4, CDCA7L, ERAP1,
HIP1, IGHM, IQGAP1, KLHL24, LEF1,
MS4A1, NT5E, PAX5, SF1
Cancer, cell death and survival,
organismal injury and abnormalities
(score = 20)
AFF3, BLNK, ETS1, FCRL5,
HSP90AB1, PITPNC1, SLC16A10,
TCL1A, TNFRSF17, TPD52, ZBTB20
Cellular development, cellular growth
and proliferation, hematological system
development and function (score = 15)
ABLIM1, AGMAT, AUTS2, IGHG1,
IGLC1, LRRN3, NOG, POU2AF1,
TSPAN13
Developmental disorder, hematological
disease, hereditary disorder (score = 2)
P2RY10
Cell-to-cell signaling and interaction,
cellular compromise, cellular function
and maintenance (score = 2)
IGHA1
TABLE 5 | Genes associated with neurological and inflammatory disorders
in young group at 48h post-injury.
Diseases p-value Genes
Neurological diseases 2.48E-02–1.20E-05 ABLIM1, AUTS2, ERAP1,
PITPNC1, TSPAN13, CDCA7L,
IGHG1, IGHM, PITPNC1,
MS4A1
Inflammatory response 3.66E-02–3.25E-05 BLNK, PAX5, POU2AF1,
IGHA1, IGHM, MS41, IGHG1,
NT5E, TCL1A, IGHM, MS4A1
immunosuppressive response that could translate to a decrease in
the number of B lymphocytes and quantity of immunoglobulin.
The role of B lymphocytes in TBI has not been established in
the literature, but some of the genes downregulated in the old
group could be involved in injury resolution. For example, BTB
and CNC homology 1 (BACH2) decreased in expression in the
old group from the acute point to follow-up point (−1.616 to
−1.849, respectively) compared to the young group. BACH2
is a coding gene for basic leucine zipper transcription factor
2, which is expressed in B cells. In humans, genome-wide
association studies link polymorphisms in the BACH2 locus to
autoimmune and inflammatory conditions (Polychronakos and
Li, 2011; International Multiple Sclerosis Genetics Consortium
et al., 2013). Preclinical models link BACH2 to regulation of
CD4+ T cells, and show that it is protective of initiating
excessive inflammation (Roychoudhuri et al., 2013). Moreover, in
preclinical models of ischemic injury, B cell deficiency was found
to exacerbate histological damage and functional outcomes, while
adoptive transfer of B cells was shown to decrease infarct size and
improve neurological deficits (Li et al., 2013). Gene expression
is also related to inflammatory regulation shown in a preclinical
model of a mild single TBIs within the hippocampus (Tweedie
et al., 2016). If indeed the gene expression profile we detected
promotes a suppression of B lymphocyte function, then this
could be a mechanism for inhibiting the neuroprotective effects
of the humoral immune response through T cell regulation
and secretion of interleukin 10, thereby contributing to worse
outcomes reported in older adults with a TBI. Future studies are
needed to examine the role of B cell-related genes in the context
of TBI and how it relates to clinical outcomes, and contributes to
age-related differences in TBI recovery.
Within the old group we also report genes within the
S100 family to be significantly upregulated at 48 h post-injury,
including S100P and S100A8. Human S100 encoding gene
contains 25 family members, which help regulate intracellular
levels of calcium (Zimmer et al., 2005), and is essential in
neuronal recovery from injury in clinical samples. Specifically,
S100B protein elevations are linked to poor prognosis following
a TBI, suggesting that gene-activity related to this neuronal
pathology following (Di Battista et al., 2015). S100P mediates cell
proliferation by binding the receptor for advanced glycation end
products to activate signaling pathways including extracellular
signal-regulated kinase and NF-κB. S100A8 is expressed in
activated macrophages and microglial cells (Beschorner et al.,
2000). S100A8+microglia are significantly increased after severe
TBI in tissue studies (Beschorner et al., 2000; Engel et al., 2000),
with those who were 69–99 years old having significantly more
activity compared to subjects 20–59 years old (Cribbs et al.,
2012). In the present study, S100A8 was significantly increased
both at 48 h and 1-week. Our findings, within the context of
previous studies, suggest that upregulated S100A8 contributes to
the differential response of the older subjects in recovery from
TBIs.
We also report that the inflammatory regulating genes like
LRRN3 and lymphoid enhancer-binding factor 1 (LEF1) were
TABLE 6 | Upregulated genes in the old compared to the young group at 48 h post-injury and its change at 1-week post-injury.
Symbol Gene name False discovery rate
(q-value) at 48 h
Fold change at
48 h
False discovery rate
(q-value) at 1-week
Fold change at
1-week
S100P S100 calcium binding protein P 0.0354 1.954 0.575 1.361
CA1 Carbonic anhydrase I 0.0235 1.905 0.361 1.630
ITGB2 Integrin, beta 2 (complement
component 3 receptor 3 and 4 subunit)
0.0344 1.898 0.583 1.480
RNASE2 Ribonuclease, RNase A family, 2 (liver,
eosinophil-derived neurotoxin)
0.0339 1.549 0.276 2.251
S100A8 S100 calcium binding protein A8 0.0212 1.515 0.230 2.469
Significance level was set at 1.5-fold change.
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highly upregulated at both time points in the young group
compared to the old group. Both of these genes are related to
T cell function and thought to be a part of immunosenescence
(Cao et al., 2010; Remondini et al., 2010). Expression of these
genes is reduced across studies of older individuals (Hong et al.,
2008; Harries et al., 2011), suggesting that older subjects are
not able to regulate inflammation as well as younger subjects
can, which may contribute to a greater burden of immune
disorders within older individuals, and a lesser ability to recover
from TBI. In support of this, in a preclinical model of mild
TBI, gene activity related to inflammation was increased in the
hippocampus following injury, and were related to neuronal
pathology, yet the impact of age was not determined (Sabir
et al., 2015). Therefore, additional studies to understand how age
impacts inflammatory activities in both clinical and preclinical
studies are needed to explicate the role of inflammation in
neuronal pathology.
After a TBI, breakdown of the BBB facilitates the passage
of inflammatory molecules and cells into a previously immune
protected environment (Das et al., 2012). Immune activities
following TBI remain poorly understood in clinical studies.
In preclinical studies we understand that coordination of
the neuroinflammatory response to TBI are essential to clear
damaged tissue and permit recovery; however, an excessive
inflammatory response, as seen in severe TBI, can be neurotoxic
(Kumar and Loane, 2012). Thus, it is a balance of immune
activities at the correct time points following TBI that are
critical, but not yet well described in clinical models of
more mild TBIs (Ziebell and Morganti-Kossmann, 2010; Corps
et al., 2015). Therefore, our finding that regulation of immune
activities at 48 h following a TBI relates to a greater rate
of MRI resolution in young TBI patients, provides initial
evidence of how immune activities regulate this complex
response.
Lastly, we found that NOG expression was also significantly
decreased in the old group from 48 h to 1-week post-injury
(−1.852 to −2.234 fold change). NOG is a protein coding gene
for noggin, an extracellular bone morphogenetic protein (BMP)
antagonist. BMP is a member of the transforming growth factor-
β superfamily that increases in cerebrospinal fluid (CSF) within
the first days after TBI from severe TBI patients (Morganti-
Kossmann et al., 1999), and is associated with neuronal repair
and neuroregeneration. Although the role of noggin as it
relates to brain injury is not well described in the clinical
literature, preclinical studies show that inhibition of BMP by
noggin promotes neurological recovery from ischemic brain
injury (Samanta et al., 2010) and recovery from intraventricular
hemorrhage (Dummula et al., 2011). Together, these preclinical
studies suggest that increased activity of noggin in the brain
enhances recovery from injury through microglial activation
and oligodendrogenesis (Bragdon et al., 2011). Moreover, BMP
(Yousef et al., 2015) and NOG (Bonaguidi et al., 2008)
signaling changes with age and relates to age-related neurological
impairments and reductions in neuroregeneration (Yousef et al.,
2015), providing some insights into our observation that this
increase in gene activity is unique to the younger TBI cohort.
By linking peripheral NOG and BMP gene-activity to resolution
of TBI-related imaging findings, we suggest that gene activity
contributes to the age disparity in neurological recovery from
TBI, because younger subjects are more likely to initiate gene-
activity changes that promote TBI recovery.
MRI can detect signs of injury including micro-hemorrhage,
small areas of contusion, or gliosis that may not be observable
by CT. MRI findings are linked to recovery at 3 months
in mild TBI patients (Yuh et al., 2013). We also report
that in the young group, there was a greater likelihood of
having no image findings related to TBI at 1-week, compared
to those in the old group. At baseline, the rates of MRI+
findings in these two groups were similar. Our findings
support previous reports of greater neurological injury in
older TBI patients, including larger lesion volumes on MRI,
despite similar types and severity of TBIs (Schonberger et al.,
2009), decreased mood and greater cognitive impairments, and
higher overall disability after TBI (Marquez de la Plata et al.,
2008).
Despite the similarities in GCS scores and mechanisms
of injury with the young and old group, we found that
the young group reported more symptoms of acute injury
including PTA and neurological symptoms based on the NSI
at both time-points. We found these results to be surprising,
as the previous literature suggests that older patients are
not necessarily under-endorsers of symptoms following a TBI
(Hukkelhoven et al., 2003; Schonberger et al., 2009). It may
be that aging occludes the changes in symptom severity or
performance and leads to older patients not linking symptoms
to the TBI, resulting in these measures of symptoms to not
be as high in older patients. This finding can be addressed
in future studies with a larger cohort and more objective
measures.
This study is limited on comparing the difference in gene
expression between young and old TBI patients, precluding
age-matched healthy, non-TBI group. Including age-matched
non-TBI subjects in the future study would provide baseline
information of gene expression changes following TBI in each
age group. This study was also limited by examining only
old and young cohorts, thereby excluding the middle aged;
however, in this initial study, this design provides for the first
examination of the impact of age on TBI recovery and biological
mechanisms. We acknowledge that the groups we used to
define young and old needs to be better addressed in a more
comprehensive fashion in future studies, yet we determined these
groups based on current studies of aging, and feel that this is
the initial step in examining the impact of age on biological
functioning.
Our findings that age influences the response to TBI provides
impetus for the consideration of age in the care of TBI patients,
and justification for future studies to elucidate therapeutic targets
that can be altered with pharmacological agents to promote
recovery from TBI in older populations who are at higher risk.
Furthermore, especially for the older group, immune-system
supportive therapy such as immune-modulating nutritional
supplements may improve the long-term outcome after TBI.
These future studies will provide critical data to elucidate
therapeutic targets that can be altered with pharmacological
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agents to promote recovery from TBI in older populations who
are at higher risk.
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